Yesterday, the CDO of Ardelyx (ARDX), David Rosenbaum, sold shares of ARDX for $10.86K.
In addition to David Rosenbaum, 3 other ARDX executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Ardelyx has an average volume of 231K.
The insider sentiment on Ardelyx has been negative according to 32 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicine for the treatment of renal diseases. It also focuses on the development of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations.
